Valneva SE stock is down -5.68% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.
Valneva SE focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia. It sells its products in the United States, Canada, Germany, Austria, Nordics, other European countries, and internationally.